Clinical Trial Update: Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A) [Phase 1, Phase 2]

View source ↗

Summary

This entry outlines a Phase 1/Phase 2 safety, tolerability, and pharmacokinetic study of recombinant human interferon alfa-2b in patients with chronic hepatitis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Interferon alfa-2b (recombinant) (interferon alfa-2b)

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Chronic Hepatitis C Virus Genotype I | Phase 1, Phase 2 | Status: UNKNOWN